Pharmacokinetics of micafungin in patients with pre-existing liver dysfunction: A safe option for treating invasive fungal infections

Concia, 2009, Epidemiology, incidence and risk factors for invasive candidiasis in high-risk patients, Drugs, 69, 5, 10.2165/11315500-000000000-00000 Sobel, 2006, The emergence of non-albicans Candida species as causes of invasive candidiasis and candidemia, Curr Infect Dis Rep, 8, 427, 10.1007/s11908-006-0016-6 Bates, 2001, Mortality and costs of acute renal failure associated with amphotericin B therapy, Clin Infect Dis, 32, 686, 10.1086/319211 Gibbs, 2005, Liposomal amphotericin B: clinical experience and perspectives, Expert Rev Anti Infect Ther, 3, 167, 10.1586/14787210.3.2.167 Kuse, 2007, Micafungin versus liposomal amphotericin B for candidaemia and invasive candidasis: a phase III randomised double-blind trial, Lancet, 369, 1519, 10.1016/S0140-6736(07)60605-9 vanBurik, 2004, Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation, Clin Infect Dis, 39, 1407, 10.1086/422312 de Wet, 2005, A randomized, double blind, comparative trial of micafungin (FK463) vs. fluconazole for the treatment of oesophageal candidiasis, Aliment Pharmacol Ther, 21, 899, 10.1111/j.1365-2036.2005.02427.x Wang, 2010, Systematic review and meta-analysis of the tolerability and hepatotoxicity of antifungals in empirical and definitive therapy for invasive fungal infection, Antimicrob Agents Chemother, 54, 2409, 10.1128/AAC.01657-09 Undre, 2012, Pharmacokinetics of micafungin in pediatric patients with invasive candidiasis and candidemia, Pediatr Infect Dis, 31, 630, 10.1097/INF.0b013e31824ab9b0 Hebert, 2005, Pharmacokinetics of micafungin in healthy volunteers, volunteers with moderate liver disease, and volunteers with renal dysfunction, J Clin Pharmacol, 45, 1145, 10.1177/0091270005279580 Valerio, 2011, Liver toxicity of micafungin. Is the drug safe?, Enferm Infecc Microbiol Clin, 29, 29, 10.1016/S0213-005X(11)70006-4 Cornely, 2011, Accumulated safety data of micafungin in therapy and prophylaxis in fungal diseases, Expert Opin Drug Saf, 10, 171, 10.1517/14740338.2011.557062 Rockey, 2010, Causality assessment in drug-induced liver injury using a structured expert opinion process: comparison to the Roussel-Uclaf causality assessment method, Hepatology, 51, 2117, 10.1002/hep.23577 Padda, 2011, Drug-induced cholestasis, Hepatology, 53, 1377, 10.1002/hep.24229 Undre, 2014, Pharmacokinetics of micafungin in subjects with severe hepatic dysfunction, Eur J Drug Metab Pharmacokinet